Finance

Lists
Q2 2027 earnings • released • EPS beat +258,45% • Revenue beat +11,57%
See results
APLLTD:NSE
Alembic Pharmaceuticals Ltd
889,80 INR
-1,86%
(-16,90) 1D
5 ნოე, 15:30:02 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for APLLTD...
Open
919,70 INR
High
936,95 INR
Low
885,60 INR
Mkt. cap
174,90 მლრ.
Avg. vol.
293,37 ათ.
Volume
1,93 მლნ.
Dividend
1,35%
Quarterly dividend
3,00 INR
Ex-dividend date
29 ივლ. 2026
P/E ratio
25,23
52-wk high
962,00 INR
52-wk low
635,80 INR
EPS
35,27 INR
Shares outstanding
188,50 მლნ.
No. of employees
17 ათ.
Open
919,70 INR
High
936,95 INR
Low
885,60 INR
Mkt. cap
174,90 მლრ.
Avg. vol.
293,37 ათ.
Volume
1,93 მლნ.
Dividend
1,35%
Quarterly dividend
3,00 INR
Ex-dividend date
29 ივლ. 2026
P/E ratio
25,23
52-wk high
962,00 INR
52-wk low
635,80 INR
EPS
35,27 INR
Shares outstanding
188,50 მლნ.
No. of employees
17 ათ.
News stories
From web sources and news partners
About Alembic Pharmaceuticals Ltd
CEO-
Employees17,2 ათ.
Founded1907
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Website-
Last report
4 ნოე. 2026
Fiscal period
Q2 2027
39,31 INR / 10,97 INR
+258,45%beat
Revenue / Est. (INR)
26,03 მლრდ. / 23,34 მლრდ.
+11,57%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
19,10 მლრდ.
18,76 მლრდ.
18,48 მლრდ.
21,50 მლრდ.
Cost of goods sold
5,16 მლრდ.
5,29 მლრდ.
6,27 მლრდ.
6,20 მლრდ.
Cost of revenue
5,16 მლრდ.
5,29 მლრდ.
6,27 მლრდ.
6,20 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,38 მლრდ.
4,33 მლრდ.
4,39 მლრდ.
4,74 მლრდ.
Operating expense
11,55 მლრდ.
11,34 მლრდ.
10,85 მლრდ.
12,96 მლრდ.
Total operating expenses
16,71 მლრდ.
16,63 მლრდ.
17,11 მლრდ.
19,16 მლრდ.
Operating income
2,40 მლრდ.
2,13 მლრდ.
1,36 მლრდ.
2,34 მლრდ.
Other non operating income
69,00 მლნ.
154,90 მლნ.
-285,60 მლნ.
149,30 მლნ.
EBT including unusual items
2,24 მლრდ.
1,61 მლრდ.
1,19 მლრდ.
2,22 მლრდ.
EBT excluding unusual items
2,24 მლრდ.
2,04 მლრდ.
1,37 მლრდ.
2,22 მლრდ.
Income tax expense
400,00 მლნ.
295,40 მლნ.
-829,00 მლნ.
495,00 მლნ.
Effective tax rate
17,88%
18,29%
-69,88%
22,31%
Other operating expenses
6,41 მლრდ.
6,21 მლრდ.
5,56 მლრდ.
7,24 მლრდ.
Net income
1,85 მლრდ.
1,33 მლრდ.
2,03 მლრდ.
1,73 მლრდ.
Net profit margin
9,67%
7,09%
10,97%
8,05%
Earnings per share
9,40
8,51
11,57
8,80
Interest and investment income
-
-
8,60 მლნ.
-
Interest expense
-242,30 მლნ.
-233,10 მლნ.
-225,60 მლნ.
-276,10 მლნ.
Net interest expenses
-242,30 მლნ.
-233,10 მლნ.
-217,00 მლნ.
-276,10 მლნ.
Depreciation and amortization charges
760,70 მლნ.
801,20 მლნ.
885,90 მლნ.
977,10 მლნ.
EBITDA
3,15 მლრდ.
2,78 მლრდ.
2,12 მლრდ.
3,09 მლრდ.
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები